Healthcare PharmaceuticalsSanofi Genzyme's high-efficacy anti-CD52 monoclonal antibody (alemtuzumab) for active relapsing-remitting multiple sclerosis, FDA approved November 14, 2014, reserved for patients with inadequate response to two or more disease-modifying therapies due to its serious risk profile and REMS program.
multiple-sclerosisalemtuzumabanti-cd52